Invasive BCIs Invasive BCI requires surgery to implant electrodes under the scalp for accessing brain signals. The main advantage is to increase accuracy. Downsides include side effects from the surgery, including scar tissue that can obstruct brain signals, or the body potentially rejecting the implanted electrodes.
Vision Invasive BCI research has targeted repairing damaged sight and providing new functionality for people with paralysis. Invasive BCIs are implanted directly into the
grey matter of the brain during neurosurgery. Because they lie in the grey matter, invasive devices produce the highest quality signals of BCI devices but are prone to
scar-tissue build-up, causing the signal to weaken, or disappear, as the body reacts to the foreign object. In
vision science, direct
brain implants have been used to treat non-
congenital (acquired) blindness. One of the first scientists to produce a working brain interface to restore sight was private researcher
William Dobelle. Dobelle's first prototype was implanted into "Jerry", a man blinded in adulthood, in 1978. A single-array BCI containing 68 electrodes was implanted onto Jerry's
visual cortex and succeeded in producing
phosphenes, the sensation of seeing light. The system included cameras mounted on glasses to send signals to the implant. Initially, the implant allowed Jerry to see shades of grey in a limited field of vision at a low frame-rate. This also required him to be hooked up to a
mainframe computer, but shrinking electronics and faster computers made his artificial eye more portable and now enable him to perform simple tasks unassisted. In 2002, Jens Naumann, also blinded in adulthood, became the first in a series of 16 paying patients to receive Dobelle's second generation implant, one of the earliest commercial uses of BCIs. The second generation device used a more sophisticated implant enabling better mapping of phosphenes into coherent vision. Phosphenes are spread out across the visual field in what researchers call "the starry-night effect". Immediately after his implant, Jens was able to use his imperfectly restored vision to
drive an automobile slowly around the parking area of the research institute. Dobelle died in 2004 before his processes and developments were documented, leaving no one to continue his work. Subsequently, Naumann and the other patients in the program began having problems with their vision, and eventually lost their "sight" again.
Movement BCIs focusing on motor neuroprosthetics aim to restore movement in individuals with paralysis or provide devices to assist them, such as interfaces with computers or robot arms. Kennedy and Bakay were first to install a human brain implant that produced signals of high enough quality to simulate movement. Their patient, Johnny Ray (1944–2002), developed '
locked-in syndrome' after a brain-stem
stroke in 1997. Ray's implant was installed in 1998 and he lived long enough to start working with the implant, eventually learning to control a computer cursor; he died in 2002 of a
brain aneurysm.
Tetraplegic Matt Nagle became the first person to control an artificial hand using a BCI in 2005 as part of the first nine-month human trial of
Cyberkinetics's
BrainGate chip-implant. Implanted in Nagle's right
precentral gyrus (area of the motor cortex for arm movement), the 96-electrode implant allowed Nagle to control a robotic arm by thinking about moving his hand as well as a computer cursor, lights and TV. One year later, Jonathan Wolpaw received the
Altran Foundation for Innovation prize for developing a Brain Computer Interface with electrodes located on the surface of the skull, instead of directly in the brain. Research teams led by the BrainGate group and another at
University of Pittsburgh Medical Center, both in collaborations with the
United States Department of Veterans Affairs (VA), demonstrated control of prosthetic limbs with many degrees of freedom using direct connections to arrays of neurons in the motor cortex of tetraplegia patients.
Communication In May 2021, a Stanford University team reported a successful proof-of-concept test that enabled a quadraplegic participant to produce English sentences at about 86 characters per minute and 18 words per minute. The participant imagined moving his hand to write letters, and the system performed handwriting recognition on electrical signals detected in the motor cortex, utilizing
Hidden Markov models and
recurrent neural networks. Since researchers from
UCSF initiated a brain-computer interface (BCI) study, numerous reports have been made. In 2021, they reported that a paralyzed and with
anarthria man was able to communicate fifteen words per minute using an implanted device that examined nerve cells controlling the muscles of the vocal tract. In addition in 2022 it was announced that their implant could also be used to spell out words and entire sentences without speaking aloud. The first bilingual speech neuroprosthesis was reported to have been developed by the same team at the University of San Francisco, in 2024. in 2025, in the beginning of the year, an article was published. The UCSF researchers reported that a man was able to control a robotic arm just by thinking. In a review article, authors wondered whether human information transfer rates can surpass that of language with BCIs. Language research has reported that information transfer rates are relatively constant across many languages. This may reflect the brain's information processing limit. Alternatively, this limit may be intrinsic to language itself, as a modality for information transfer. In 2023 two studies used BCIs with recurrent neural network to decode speech at a record rate of 62 words per minute and 78 words per minute.
Technical challenges There exist a number of technical challenges to recording brain activity with invasive BCIs. Advances in
CMOS technology are pushing and enabling integrated, invasive BCI designs with smaller size, lower power requirements, and higher signal acquisition capabilities. Invasive BCIs involve electrodes that penetrate brain tissue in an attempt to record
action potential signals (also known as spikes) from individual, or small groups of, neurons near the electrode. The interface between a recording electrode and the electrolytic solution surrounding neurons has been modelled using the
Hodgkin-Huxley model. Electronic limitations to invasive BCIs have been an active area of research in recent decades. While
intracellular recordings of neurons reveal action potential voltages on the scale of hundreds of millivolts, chronic invasive BCIs rely on recording extracellular voltages which typically are three orders of magnitude smaller, existing at hundreds of microvolts. Further adding to the challenge of detecting signals on the scale of microvolts is the fact that the electrode-tissue interface has a high
capacitance at small voltages. Due to the nature of these small signals, for BCI systems that incorporate functionality onto an integrated circuit, each electrode requires its own
amplifier and
ADC, which convert analog extracellular voltages into digital signals. Challenges existing in the area of
material science are central to the design of invasive BCIs. Variations in signal quality over time have been commonly observed with implantable microelectrodes. Optimal material and mechanical characteristics for long term signal stability in invasive BCIs has been an active area of research. It has been proposed that the formation of
glial scarring, secondary to damage at the electrode-tissue interface, is likely responsible for electrode failure and reduced recording performance. As a result, flexible and tissue-like designs have been researched and developed to minimize
foreign-body reaction by means of matching the
Young's modulus of the electrode closer to that of brain tissue.
Endovascular A systematic review published in 2020 detailed multiple clinical and non-clinical studies investigating the feasibility of endovascular BCIs. In 2010, researchers affiliated with University of Melbourne began developing a BCI that could be inserted via the vascular system. Australian neurologist
Thomas Oxley conceived the idea for this BCI, called Stentrode, earning funding from
DARPA. Preclinical studies evaluated the technology in sheep. This proximity enables Stentrode to measure neural activity. The procedure is most similar to how venous sinus stents are placed for the treatment of
idiopathic intracranial hypertension. Stentrode communicates neural activity to a battery-less telemetry unit implanted in the chest, which communicates wirelessly with an external telemetry unit capable of power and data transfer. While an endovascular BCI benefits from avoiding a
craniotomy for insertion, risks such as
clotting and
venous thrombosis exist.